Biotech firm Pharming losses widen
Leiden-based biotech firm Pharming announced on Friday a net loss in the third quarter of 2008 of €7.2m, up from €6.4m in the year earlier period.
Turnover in the first nine months of the year dropped to €400,000 compared with €600,000 in the same period in 2007. The cash position improved from €14.1m in 2007 to €33.7m in 2008.
In a statement, Pharming CEO Francis Pinto confirmed the company is pressing ahead with its application for official approval of Rhucin to treat allergic swelling reactions known as angioedema.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.
Make a donation